Australia has some of the most potently venomous snakes on Earth and loses about two people a year. India loses about 58,000. The venom is not what decides it. What decides it is how far the nearest vial is, who can pay for it, and whether the road holds up in the rain. Snakebite is the deadliest of the neglected tropical diseases — and the most fixable.
138,000
deaths a year at the top of the WHO's estimated range of 81,410–137,880 — roughly one death every four to six minutes, almost all of them in rural Asia and sub-Saharan Africa. For every person killed, about three more survive with an amputation or a permanent disability. World Health Organization, fact sheet, 2023
01 — The scale
Five million bites, narrowing to a hundred thousand graves
Most bites are dry or minor. The funnel from contact to death is steep — and every step down it is a step where medicine could intervene.
Bites per year
5,400,000WHO 2023
Envenomings
1.8–2.7 Mvenom injected
Amputations & permanent disability
~400,000survivors / year
Deaths
81k–138kWHO range
Bars are linear and share one scale — each is drawn against the 5.4 million bites at the top. The disability and death bars use the upper end of the WHO range.
3,000+
Snake species
Of these, about 600 are venomous and just over 200 are medically important — capable of killing or maiming a person.
57%
Of bites envenom
Across 49,920 examined cases in a 2024 global review, more than half of bites delivered venom. 56% landed on a leg or foot.
2017
Year it was listed
Snakebite was only added to the WHO's list of highest-priority neglected tropical diseases in June 2017.
02 — Where
A belt around the tropics
Snakebite deaths concentrate almost entirely between the Tropic of Cancer and the Tropic of Capricorn, where venomous species, barefoot farm work and thin rural health systems overlap. Shading below is regional death rate per 100,000 people per year.
Under 0.050.030.440.96 deaths per 100,000 / yr
Schematic map — continent outlines are hand-simplified, not survey-accurate. Regional rates from a 2024 systematic review of 663,460 snakebites across 29 countries (PLOS NTD). Country death counts: India from the Million Death Study (eLife, 2020); Africa from Nature Communications, 2024.
03 — The spectrum
Same bite, hundred-fold difference in odds
Deaths per 100,000 people per year, by region. One hue, low to high. The gap between the ends of this strip is not a gap in biology — it is a gap in emergency rooms.
0.01Europe
0.03Americas
0.44Africa
0.96Asia
Deaths per year — log scale
Australia ~3,000 bites/yr
2average / year
United States 7,000–8,000 bites/yr
5average / year
Sub-Saharan Africa 500,000+ envenomings
~30,000per year
India ~half the world's total
58,000per year
Log scale (base 10), so bar length compresses a 29,000-fold range. Australia is home to some of the most potently venomous snakes on Earth and still records roughly two deaths a year, because bites reach hospitals with antivenom in hours.
04 — The calendar
It follows the rain
In India, snakebite deaths track the monsoon: flooded burrows push snakes into fields and homes exactly when farmers are barefoot in wet paddy and rural roads are worst. Half of all deaths fall between June and September.
Illustrative curve. The two labelled points — a mid-July peak of 294 deaths per day and a mid-February trough of 78 — are measured values from the Million Death Study (Suraweera et al., eLife 2020), as is the finding that half of deaths occur June–September. The month-to-month shape between them is drawn to fit those anchors and the study's ~58,000 annual average; it is not a published monthly series.
94%
Of deaths are rural
Almost none of this happens in cities. Bites cluster in low-altitude farmland during planting and harvest.
77%
Died outside hospital
Most Indian victims never reached a facility at all. In Africa, roughly 80% see only a traditional healer, or no one.
1 in 250
Lifetime risk, India
An Indian's chance of dying of snakebite before age 70 — approaching 1 in 100 in the worst districts.
05 — The trend
Falling, but not fast enough
Global snakebite mortality is dropping as rural health care spreads. The WHO wants it halved by 2030. On the current path, modellers say it won't be.
Measured, 1990–2019WHO 2030 target (halve the 2019 rate)
Measured endpoints: 63,400 deaths in 2019 (uncertainty 38,900–78,600) at an age-standardised rate of 0.8 per 100,000, a 36% fall since 1990 — Global Burden of Disease analysis, Nature Communications, 2022. Derived / illustrative: the 1990 value of 1.25 is back-calculated from that 36% decline; the straight path between endpoints is schematic. The study's own conclusion — that the forecast decline falls short of the WHO 2030 goal — is not.
06 — The price
A cure that exists, priced past the people who need it
Antivenom has worked since Albert Calmette produced the first therapeutic serum in 1895. The problem is a market: the patients are the world's poorest farmers, the product needs a cold chain, and manufacturers keep walking away.
Share of surveyed facilities with antivenom actually in stock, 2023
Uganda
4.2%in stock
Rwanda
4.2%in stock
Zambia
7.6%in stock
Bars run 0–100% of facilities. Health economics of snakebite envenomation: a sub-Saharan African perspective, Trans. R. Soc. Trop. Med. Hyg., 2024.
$200+
A full course
A severe envenoming needs several vials. The bill can exceed a subsistence farming household's entire annual income.
$83–281
Per healthy year saved
Cost per DALY averted across 16 West African countries — by global health standards, strikingly cheap.
1
Maker in sub-Saharan Africa
One regional manufacturer serves the continent. The broad-spectrum product Fav-Afrique was discontinued in 2014 for being unprofitable.
$20.8 bn
Spent on HIV/AIDS in low- and middle-income countries, 2022
Snakebite research funding over the same period is described in the literature as negligible. Both are diseases of poverty; only one has a constituency.
3.8 hrs
Median time to antivenom, rural Sri Lanka
Only 8% of patients were treated within two hours of the bite. In parts of Africa, admission delays routinely exceed 24 hours.
Why it matters
This is a solved problem waiting on logistics
Nobody has to invent anything. Antivenom has worked for 130 years, it costs a few hundred dollars, and the countries that stock it near their farms have all but eliminated snakebite death. The 100,000 people who die each year are dying of distance, cost and inattention — three things that respond to money and policy far faster than a disease responds to research.
If you're near snakes: a bite needs a hospital, not a tourniquet, not cutting, not ice, not suction. Immobilise the limb, keep it below the heart, and move the person — not the limb — to care fast.
Photograph the snake only if it's safe. Species identification changes which antivenom is given; chasing the snake kills people.
Rubber boots and a torch are the highest-yield public health intervention in this whole story. Most bites are to the lower leg, at dusk, on foot.
Where to look: WHO's snakebite programme, the Global Snakebite Initiative, and MSF's Access Campaign all publish where the antivenom gaps are and who is trying to close them.
Sources & notes
World Health Organization, "Snakebite envenoming" fact sheet, 12 September 2023 — 5.4 million bites, 1.8–2.7 million envenomings, 81,410–137,880 deaths, ~3× as many permanent disabilities, 3,000+ snake species / ~600 venomous / 200+ medically important, 2030 target of a 50% reduction, 2017 listing as a highest-priority NTD.
Suraweera, W. et al., "Trends in snakebite deaths in India from 2000 to 2019 in a nationally representative mortality study," eLife, 2020 (Million Death Study, Centre for Global Health Research) — 1.2 million deaths over 2000–2019, ~58,000/year; 94% rural; 77% died outside hospital; mid-July peak of 294 deaths/day and mid-February trough of 78/day; half of deaths June–September; lifetime risk ~1 in 250 before age 70, approaching 1 in 100 in hotspots; Russell's viper 43% of identified bites.
GBD 2019 Snakebite Collaborators, "Global mortality of snakebite envenoming between 1990 and 2019," Nature Communications, 25 October 2022 — 63,400 deaths in 2019 (38,900–78,600), age-standardised rate 0.8 per 100,000, a 36% decline since 1990; India highest burden; forecast decline insufficient to meet the WHO 2030 goal.
Systematic review and meta-analysis of global snakebite morbidity and mortality, PLOS Neglected Tropical Diseases, 2024 — 65 studies, 663,460 bites, 29 countries, 2001–2022. Mortality per 100,000/yr: Asia 0.96, Africa 0.44, South America 0.03, North America 0.03, Europe 0.01. 57.3% of examined cases envenomed; 56.4% of bites to the lower limb.
"Snakebite envenoming in Africa remains widely neglected and demands multidisciplinary attention,"Nature Communications, 2024 — 500,000+ envenomings and ~30,000 deaths a year in Africa; ~80% of victims use only traditional healers or receive no treatment; one antivenom manufacturer in sub-Saharan Africa; Fav-Afrique discontinued in 2014; admission delays frequently exceeding 24 hours; US$20.8 bn spent on HIV/AIDS in low- and middle-income countries in 2022 against negligible snakebite funding.
"Health economics of snakebite envenomation: a sub-Saharan African perspective,"Transactions of the Royal Society of Tropical Medicine and Hygiene, 2024 — antivenom in stock at 4.2% of surveyed facilities in Uganda, 7.6% in Zambia, 4.2% in Rwanda (2023); full treatment courses exceeding US$200.
Habib, A.G. et al., "Cost-effectiveness of antivenoms for snakebite envenoming in 16 countries in West Africa," PLOS Neglected Tropical Diseases, 2016 — US$83 per DALY averted in Benin to US$281 in Sierra Leone.
US CDC / NIOSH, "Venomous Snakes at Work" — 7,000–8,000 venomous bites and about 5 deaths per year in the United States. Australian Venom Research Unit, University of Melbourne — roughly 3,000 bites and an average of about 2 deaths a year in Australia.
"Time delays in treatment of snakebite patients in rural Sri Lanka and the need for rapid diagnostic tests,"PLOS Neglected Tropical Diseases, 2020 — median 3.8 hours from bite to antivenom; 8% treated within two hours.
Bon, C., "Doctor Albert Calmette 1863–1933: founder of antivenomous serotherapy and of antituberculous BCG vaccination," Toxicon, 1999 — Calmette produced the first therapeutic anti-cobra serum at the Institut Pasteur de Lille in 1895.
Flagged as illustrative: the month-by-month curve in section 04 (anchored on the study's measured July peak, February trough and annual total); the straight 1990–2019 path, and the back-calculated 1.25 per 100,000 value for 1990 in section 05; and the hand-simplified continent outlines on the map in section 02. All headline figures are as published.